SCHEMBL769985

SCHEMBL769985

CC(=O)Nc1cccc(-c2cn(C)c(=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)c1C

nearest known ligand 0.84

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1070021 0.90 BTK (0.90) BTK
SCHEMBL1069548 0.90 BTK (0.88) BTK
SCHEMBL29359902 0.89 BTK (1.00) BTK
SCHEMBL769731 0.89 BTK (1.00) BTK
SCHEMBL1069586 0.88 BTK (0.87) BTK
SCHEMBL1068170 0.88 BTK (0.86) BTK
SCHEMBL1067840 0.88 BTK (1.00) BTK
SCHEMBL1070359 0.88 BTK (0.86) BTK
SCHEMBL1068122 0.88 BTK (1.00) BTK
SCHEMBL1068043 0.88 BTK (0.86) BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014157-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) PHARMACYCLICS LLC (US) 2026-01-15 US disclosed
US-20250127781-A1 USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) PHARMACYCLICS, INC. 2025-04-24 US disclosed
US-20240065971-A1 METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC (US) 2024-02-29 US disclosed
US-20230293532-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) PHARMACYCLICS LLC (US) 2023-09-21 US disclosed
US-20230248730-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) PHARMACYCLICS LLC (US) 2023-08-10 US disclosed
US-11672803-B2 Use of inhibitors of Brutons tyrosine kinase (Btk) PHARMACYCLICS LLC (US) 2023-06-13 US disclosed
US-20220249494-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) PHARMACYCLICS LLC (US) 2022-08-11 US disclosed
US-20220175785-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) PHARMACYCLICS LLC (US) 2022-06-09 US disclosed
US-20210361657-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) PHARMACYCLICS LLC (US) 2021-11-25 US disclosed
US-20210169885-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) PHARMACYCLICS LLC 2021-06-10 US disclosed
US-20130178483-A1 Methods and Compositions for Inhibition of Bone Resorption PHARMACYCLICS, INC. (US) 2013-07-11 US disclosed
CN-103153311-A Use of Bruton's Tyrosine Kinase (BTK) Inhibitors PHARMACYCLICS INC 2013-06-12 CN disclosed
WO-2013059738-A2 USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) PHARMACYCLICS, INC. (US) 2013-04-25 WO disclosed
EP-2575818-A2 THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Pharmacyclics, Inc. (US) 2013-04-10 EP disclosed
WO-2013003629-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF BONE RESORPTION PHARMACYCLICS, INC. (US) 2013-01-03 WO disclosed
US-20120183535-A1 USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) PHARMACYCLICS, INC. (US) 2012-07-19 US disclosed
US-20120100138-A1 THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) PHARMACYCLICS, INC. (US) 2012-04-26 US disclosed
US-20120087915-A1 USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) PHARMACYCLICS, INC. (US) 2012-04-12 US disclosed
US-20120071497-A1 METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. (US) 2012-03-22 US disclosed
WO-2011153514-A2 THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) PHARMACYCLICS, INC. (US) 2011-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210169885-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, LYN, SYK BTK 1/4885
US-20210361657-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, LYN, SYK BTK 1/4885
US-20120071497-A1 METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, BCL6, BCL6B BTK 1/4885
US-20260014157-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, BCL6B, BCL9 BTK 1/4885
US-20240065971-A1 METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE BTK, BCL6, BCL6B BTK 1/4885
US-20220249494-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, LYN, SYK BTK 1/4885
US-20130178483-A1 Methods and Compositions for Inhibition of Bone Resorption BTK, CTTN, BMX BTK 1/4885
US-20230248730-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, LYN, SYK BTK 1/4885
US-11672803-B2 Use of inhibitors of Brutons tyrosine kinase (Btk) BTK, LYN, SYK BTK 1/4885
US-20250127781-A1 USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) BTK, LYN, SYK BTK 1/4885
US-20230293532-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, LYN, SYK BTK 1/4885
US-20220175785-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, LYN, SYK BTK 1/4885
US-20120087915-A1 USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) BTK, SYK, LYN BTK 1/4885
US-20120183535-A1 USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) BTK, SYK, LYN BTK 1/4885
US-20120100138-A1 THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) BTK, SYK, LYN BTK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.